TrialJournal of the European Academy of Dermatology and Venereology : JEADV2021

Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY).

J Bagel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.